Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
Alector (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on neurodegeneration therapies, has scheduled its fourth quarter and full-year 2024 earnings conference call for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The company will release its Q4 2024 financial results before the call and provide a comprehensive business update during the event.
The conference call will be accessible via webcast through Alector's investor relations website, with a 30-day replay available afterward. Phone participants must register online to receive dial-in details and a personal PIN for access.
Alector (Nasdaq: ALEC), un'azienda biotecnologica in fase avanzata focalizzata sulle terapie per la neurodegenerazione, ha programmato la sua conferenza telefonica sugli utili del quarto trimestre e dell'intero anno 2024 per mercoledì 26 febbraio 2025, alle 16:30 ET/13:30 PT. L'azienda rilascerà i risultati finanziari del Q4 2024 prima della chiamata e fornirà un aggiornamento completo sulle attività durante l'evento.
La conferenza telefonica sarà accessibile tramite webcast attraverso il sito web delle relazioni con gli investitori di Alector, con una registrazione disponibile per 30 giorni dopo. I partecipanti telefonici devono registrarsi online per ricevere i dettagli per la chiamata e un PIN personale per l'accesso.
Alector (Nasdaq: ALEC), una empresa biotecnológica en etapa avanzada centrada en terapias para la neurodegeneración, ha programado su conferencia telefónica sobre resultados del cuarto trimestre y del año completo 2024 para miércoles 26 de febrero de 2025, a las 4:30 p.m. ET/1:30 p.m. PT. La empresa publicará sus resultados financieros del cuarto trimestre de 2024 antes de la llamada y proporcionará una actualización completa del negocio durante el evento.
La conferencia telefónica será accesible a través de un webcast en el sitio web de relaciones con inversores de Alector, con una repetición disponible durante 30 días después. Los participantes por teléfono deben registrarse en línea para recibir los detalles de acceso y un PIN personal.
Alector (Nasdaq: ALEC)는 신경퇴행성 질환 치료에 중점을 둔 후기 단계 임상 생명공학 회사로, 2024년 4분기 및 연간 실적 컨퍼런스 콜을 2025년 2월 26일 수요일 오후 4시 30분 ET/오후 1시 30분 PT에 예정했습니다. 회사는 콜 전 2024년 4분기 재무 결과를 발표하고, 행사 중에 포괄적인 사업 업데이트를 제공할 것입니다.
컨퍼런스 콜은 Alector의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있으며, 이후 30일 동안 다시 들을 수 있습니다. 전화 참가자는 접속 세부정보와 개인 PIN을 받기 위해 온라인으로 등록해야 합니다.
Alector (Nasdaq: ALEC), une entreprise biopharmaceutique en phase avancée axée sur les thérapies de neurodégénérescence, a programmé sa conférence téléphonique sur les résultats du quatrième trimestre et de l'année 2024 pour mercredi 26 février 2025, à 16h30 ET/13h30 PT. L'entreprise publiera ses résultats financiers du Q4 2024 avant l'appel et fournira une mise à jour complète de ses activités pendant l'événement.
La conférence téléphonique sera accessible par webcast via le site web des relations investisseurs d'Alector, avec une rediffusion disponible pendant 30 jours après. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les détails de connexion et un code PIN personnel pour l'accès.
Alector (Nasdaq: ALEC), ein Unternehmen der späten klinischen Phase, das sich auf Therapien gegen Neurodegeneration konzentriert, hat seine Konferenzschaltung zu den Ergebnissen des vierten Quartals und des gesamten Jahres 2024 für Mittwoch, den 26. Februar 2025, um 16:30 Uhr ET/13:30 Uhr PT angesetzt. Das Unternehmen wird die finanziellen Ergebnisse für Q4 2024 vor dem Anruf veröffentlichen und während der Veranstaltung ein umfassendes Geschäftsupdate bereitstellen.
Die Konferenzschaltung wird über einen Webcast auf der Investor-Relations-Website von Alector zugänglich sein, mit einer 30-tägigen Wiederholung danach. Telefonteilnehmer müssen sich online registrieren, um die Einwahldaten und eine persönliche PIN für den Zugang zu erhalten.
- None.
- None.
Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call.
The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer’s disease, Parkinson's disease, and Lewy body dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
212-600-1494
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
When is Alector (ALEC) releasing its Q4 2024 earnings?
How can investors access Alector's (ALEC) Q4 2024 earnings call?
How long will Alector's (ALEC) Q4 2024 earnings call replay be available?
What will be covered in Alector's (ALEC) February 26, 2025 conference call?
